compliance risk+assessment+ · principles of compliance programs for pharmaceutical manufacturers...

16
Compliance Risk Assessment the Heat Map Tomasz Kruk / Istanbul / May 2011

Upload: others

Post on 04-Aug-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Compliance  Risk  Assessment  the  Heat  Map    

                 

Tomasz  Kruk  /  Istanbul  /  May  2011  

Page 2: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Plan  

1.  The  Risk  Assessment  vs  The  Effec3ve  Compliance  Program  

2.  The  Heat  Map  –  external  sources  

3.  The  Heat  Map  –  internal  sources  

4.  Discussion  

Page 3: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

SUBJECT:   Elements  for  an  Effec/ve  Compliance  Program    

AUTHOR:   Office  of  Inspector  General  /  Dept.  of  Health  &  Human  Services  DOCUMENT  TITLE:   OIG  Compliance  Program  Guidance  for  Pharmaceu/cal  Manufacturers  PUBLISHED:   April  18,  2003  TARGET:   reducing  fraud  and  abuse  in  federal  health  care  programs  /    At  a  minimum,  a  

comprehensive  compliance  program  should  include  the  following  elements:  

(5)  The  use  of  audits  and/or  other  risk  evaluaPon  techniques  to  monitor  compliance,  iden/fy  problem  areas,  and  assist  in  the  reduc/on  of  iden/fied  problems;  

Five  approaches  to  effec2ve  compliance  program  -­‐  RISK  ASSESSMENT  -­‐  I  

Compliance Program Guidance for Pharmaceutical Manufacturers developed by the Office of Inspector General (OIG). Through this notice, the OIG is setting forth its general views on the value and fundamental principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when developing and implementing an effective compliance program. - Compliance program guidance is a major initiative of the OIG in its effort to engage the health care community in preventing and reducing fraud and abuse in federal health care programs.

Page 4: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

SUBJECT:   Six Principles for Bribery Prevention  

AUTHOR:   Ministry  of  Jus/ce  /  UK  DOCUMENT  TITLE:   Consulta/on  on  guidance  about  commercial  organisa/ons  preven/ng  bribery  PUBLISHED:   Sept.  2010  TARGET:   fighPng  corrupPon  

1/  Risk  Assessment  –  this  is  about  knowing  and  keeping  up  to  date  with  the  bribery  risks  you  face  in  your  sector  and  market;  

Five  approaches  to  effec2ve  compliance  program  -­‐  RISK  ASSESSMENT  -­‐  II  

Consultation on guidance about commercial organisations preventing bribery (section 9 of the Bribery Act 2010) Consultation Paper CP11/10 This consultation begins on 14 September 2010 This consultation ends on 8 November 2010 http://www.justice.gov.uk/consultations/docs/bribery-act-guidance-consultation1.pdf

Page 5: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

SUBJECT:   EFFECTIVE COMPLIANCE AND ETHICS PROGRAM (Nov.2010)  

AUTHOR:   United  States  Sentencing  Commission  DOCUMENT  TITLE:   United  States  Sentencing  Commission  -­‐  Guidelines  Manual  PUBLISHED:   Nov.  2010  TARGET:   The  existence  of  an  effec/ve  compliance  and  ethics  program  mi/gate  the  ul/mate  

punishment  of  an  organizaPon.  

In  implemen/ng  the  Program,  the  organiza/on  shall  periodically  assess  the  risk  of  criminal  conduct  and  shall  take  appropriate  steps  to  design,  implement,  or  modify  each  requirement  set  forth  above  to  reduce  the  risk  of  criminal  conduct  iden/fied  through  this  process.  

Five  approaches  to  effec2ve  compliance  program  -­‐  RISK  ASSESSMENT  -­‐  III  

The United States Sentencing Commission - Guidelines Manual, Chapter 8 Sentencing of Organizations, Part B Remedying Harm from Criminal Conduct and Effective Compliance and Ethics Program

Page 6: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

SUBJECT:   Good Practice Guidance for Companies  

AUTHOR:    OECD  DOCUMENT  TITLE:   OECD  Good  Prac/ce  Guidance  for  Companies  PUBLISHED:   Feb  18,  2010  TARGET:   This  “Guidance”  is  addressed  to  companies  for  establishing  and  ensuring  the  

effec/veness  of  internal  controls,  ethics,  and  compliance  programmes  or  measures  for  prevenPng  and  detecPng  the  bribery  of  foreign  public  officials  in  their  interna/onal  business  transac/ons  (…)  

Effec/ve  internal  controls,  ethics,  and  compliance  programmes  or  measures  for  preven/ng  and  detec/ng  foreign  bribery  should  be  developed  on  the  basis  of  a  risk  assessment  addressing  the  individual  circumstances  of  a  company,  in  par/cular  the  foreign  bribery  risks  facing  the  company  (such  as  its  geographical  and  industrial  sector  of  opera/on).  

Five  approaches  to  effec2ve  compliance  program  -­‐  RISK  ASSESSMENT  -­‐  IV  

Good Practice Guidance on Internal Controls, Ethics, and Compliance Adopted 18 February 2010 This Good Practice Guidance was adopted by the OECD Council as an integral part of the Recommendation of the Council for Further Combating Bribery of Foreign Public Officials in International Business Transactions of 26 November 2009. http://www.oecd.org/dataoecd/5/51/44884389.pdf

Page 7: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

SUBJECT:   CORPORATE  COMPLIANCE  PROGRAM  AUTHOR:   The  United  States  Department  of  Jus/ce,  Criminal  Division,  Fraud  Sec/on  DOCUMENT  TITLE:   Prosecu/on  Agreements  PUBLISHED:    Nov.  2010  TARGET:   This  is  part  of  a  few  recent  prosecu/on  agreements  where  companies  have  been  

obliged  to  develop  and  promulgate  a  clearly  ar/culated  and  visible  corporate  policy  against  violaPons  of  the  FCPA)  

4.  The  Company  will  develop  these  compliance  standards  and  procedures,  including  internal  controls,  ethics,  and  compliance  programs  on  the  basis  of  a  risk  assessment  addressing  the  individual  circumstances  of  the  Company,  in  par/cular  the  foreign  bribery  risks  facing  the  Company,  including,  but  not  limited  to,  its  geographical  organiza/on,  interac/ons  with  various  types  and  levels  of  government  officials,  industrial  sectors  of  opera/on,  involvement  in  joint  venture  arrangements,  importance  of  licenses  and  permits  in  the  company's  opera/ons,  degree  of  governmental  oversight  and  inspec/on,  and  volume  and  importance  of  goods  and  personnel  clearing  through  customs  and  immigra/on.  

Five  approaches  to  effec2ve  compliance  program  -­‐  RISK  ASSESSMENT  -­‐  V  

CORPORATE COMPLIANCE PROGRAM is a part of the Nov. 2010 PROSECUTION AGREEMENTS: United States vs. Panalpina Inc.: Plea Agreement http://www.justice.gov/opa/documents/panalpina-inc-plea-agreement.pdf or United States vs. Shell: Deferred Prosecution Agreement http://www.justice.gov/opa/documents/shell-dpa.pdf

Page 8: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Transparency  Interna2onal  INDEX    -­‐  the  Heat  Map  (external  sources)  

Page 9: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Interna2onal  Human  Development  INDEX    -­‐  the  Heat  Map  (external  sources)  

http://hdr.undp.org/en/data/map/

Page 10: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

OECD  Conven2on  on  Comba2ng  Bribery…    -­‐  the  Heat  Map  (external  sources)  

Page 11: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Economic  Freedom  INDEX    -­‐  the  Heat  Map  (external  sources)  

http://www.heritage.org/index/download

Page 12: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Number  of  legal  en22es  by  country    -­‐  the  Heat  Map  (internal  sources)  

12

Page 13: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Number  of  employees  by  country    -­‐  the  Heat  Map  (internal  sources)  

13

Page 14: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Revenue  by  country    -­‐  the  Heat  Map  (internal  sources)  

14

Page 15: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

Discussion  

15

Page 16: Compliance Risk+Assessment+ · principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when

16

Tomasz Kruk - Global Compliance Counsel [email protected] mobile +41 079 909 7346

Questions?